Figure 1
Study design. The phase 1/2a study was a dose-escalation, sequential design to evaluate the safety and PK of rFVIIIFc compared with rFVIII after a single intravenous dose of either 25 IU/kg (low-dose cohort) or 65 IU/kg (high-dose cohort).
Study design. The phase 1/2a study was a dose-escalation, sequential design to evaluate the safety and PK of rFVIIIFc compared with rFVIII after a single intravenous dose of either 25 IU/kg (low-dose cohort) or 65 IU/kg (high-dose cohort).
